Fuzheng Huayu Capsule Improves Survival in Patients with Hepatitis B-related Cirrhosis and Overt Hepatic Encephalopathy

Objective: Fuzheng Huayu (FZHY) capsules exert anti-liver fibrosis and cirrhosis effects. This study aimed to determine the effect of FZHY on 6-month survival rate patients with overt hepatic encephalopathy (OHE) hepatitis B-related (HBC). Methods: A total 517 OHE HBC treated between January 2008 July 2018 were enrolled. Patients divided into (n = 129) control groups 388), rates compared two groups. Propensity score matching (PSM) was used reduce bias caused by confounding factors. Results: In multivariable regression analysis, therapy an independent protective factor survival. After PSM (1:2), group comprised 126 252 patients, respectively. The remarkably higher in than (P < 0.005). users, especially those a model for end-stage liver disease ≥ 20 Child-Pugh class C, benefited significantly from therapy. Conclusions: Adjuvant may be associated improved HBC. However, further clinical studies are required validate our findings.